Novel systmen for predicting adverse effect of neuropathy in oxaliplatin based chemotherapy

2017 Fiscal Year Final Research Report

• Project/Area Number: 15K08085
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Medical pharmacy
• Research Institution: Kyoto Pharmaceutical University
• Principal Investigator: Ito Yukako 京都薬科大学, 薬学部, 講師 (30278444)
• Co-Investigator(Renkei-kenkyūsha): Sakaeda Toshiyuki 京都薬科大学, 薬物動態学分野, 教授 (00304098)
• Project Period (FY): 2015-04-01 – 2018-03-31
• Keywords: PK/PD解析 / 抗がん剤 / オキサリプラチン / 末梢神経障害

Outline of Final Research Achievements

Oxaliplatin (L-OHP) has been developed as a third-generation platinum compound for the treatment of gastroenterological cancer in chemotherapy, including FOLFOX, CapOX, SOX, and FOLFIRINOX. Undesirable side effects, such as emesis, diarrhea, nausea, vomiting, muscle pain, joint pain, and peripheral neuropathy, cause discontinuation of therapy, indicating inadequate treatment. L-OHP-induced　neuropathy　is　predominant　reason　for　extension　of　the　withdrawal period, and termination of therapy. Two different strategies have been advocated to prevent L-OHP-induced neuropathy: a Stop-and -Go approach and the concurrent use of neuromodulatory agents, including antidepressants, antiepileptics, or calcium and magnesium infusions. However, neither strategy is sufficiently effective. In order to prevent serious side effects and safely complete the chemotherapy regimen, this study investigated the pharmacokinetic and toxicodynamic properties of L-OHP in colorectal cancer model rats.

Free Research Field

薬物動態学　DDS　PK/PD解析　抗がん剤